<?xml version="1.0" encoding="UTF-8"?>
<p id="Par53">For a consistent global approach to the periodic evaluation of a medicinal product’s benefit–risk profile, the IPVG recommends the use of the PBRER format as outlined by the ICH E2C guidance [
 <xref ref-type="bibr" rid="CR14">14</xref>].
</p>
